{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:23:01Z","timestamp":1792110181724,"version":"4.4.0"},"reference-count":103,"publisher":"Asia Pacific Academy of Ophthalmology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia Pac J Ophthalmol (Phila)"],"published-print":{"date-parts":[[2019]]},"DOI":"10.22608\/apo.2018127","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T04:52:13Z","timestamp":1530507133000},"source":"Crossref","is-referenced-by-count":11,"title":["Steroid Treatment of Optic Neuropathies"],"prefix":"10.22608","member":"9895","published-online":{"date-parts":[[2019]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Quigley HA, Addicks EM, Green R. Optic nerve damage in human glaucoma. Arch Ophthalmol. 1982;100:135\u2013146.","DOI":"10.1001\/archopht.1982.01030030137016"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Harweth RS, Crawford MLJ, Frishman LJ, et al. Visual field defects and neural losses from experimental glaucoma. Prog Retin Eye Res. 2002;21:91\u2013125.","DOI":"10.1016\/S1350-9462(01)00022-2"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Galv\u00e3o Filho RP, Vessani RM, Susanna R. Comparison of retinal nerve fibre layer thickness and visual field loss between different glaucoma groups. Br J Ophthalmol. 2005;89:1004\u20131007.","DOI":"10.1136\/bjo.2004.050906"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Alasil T, Wang K, Yu F, et al. Correlation of retinal nerve fiber layer thickness and visual fields in glaucoma. Am J Ophthalmol. 2014;157:953\u2013959.","DOI":"10.1016\/j.ajo.2014.01.014"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Wollstein G, Kagemann L, Bilonick RA. Retinal nerve fibre layer and visual function loss in glaucoma: the tipping point. Br J Ophthalmol. 2012;96:47\u201352.","DOI":"10.1136\/bjo.2010.196907"},{"key":"ref=6","unstructured":"Waller DG, Sampson AP, Renwick AG, et al. Chapter 44: Corticosteroids (glucocorticoids and mineralocorticoids). In: Waller DG, Sampson AP, Renwick AG, et al, eds. Medical Pharmacology and Therapeutics. 4th ed. Edinburgh, UK: Saunders\/Elsevier; 2014:501\u2013509."},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Barnes PJ. How corticosteroids control inflammation. Quintiles Prize Lecture 2005. Br J Pharmacol. 2006;148:245\u2013254.","DOI":"10.1038\/sj.bjp.0706736"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013;4(Suppl 1):S94\u2013S98.","DOI":"10.4103\/0976-500X.120975"},{"key":"ref=9","unstructured":"Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14:203\u2013207."},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420\u2013426.","DOI":"10.1002\/art.21984"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Morrow MJ, Ko MW. Should oral corticosteroids be used to treat demyelinating optic neuritis? J Neuroophthalmol. 2017;37:444\u2013450.","DOI":"10.1097\/WNO.0000000000000555"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Hr\u00f3bjartsson A, Kaptchuk TH, Miller FG. Placebo effect studies are susceptible to response bias and to other types of biases. J Clin Epidemiol. 2011;64:1223\u20131229.","DOI":"10.1016\/j.jclinepi.2011.01.008"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Morton V, Torgerson DJ. Effect of regression to the mean on decision making in health care. BMJ. 2003;326:1083\u20131084.","DOI":"10.1136\/bmj.326.7398.1083"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Sackett DL, Sinclair JC, et al. Users\u2019 guides to the medical literature. IX. A method for grading health care recommendations. JAMA. 1995;274:1800\u20131804.","DOI":"10.1001\/jama.1995.03530220066035"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technol Assess. 2001;5:1\u201369.","DOI":"10.3310\/hta5160"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Optic Neuritis Study Group. The clinical profile of optic neuritis experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109:1673\u20131678.","DOI":"10.1001\/archopht.1991.01080120057025"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Bee, YS, Lin MC, Wang CC, et al. Optic neuritis: clinical analysis of 27 cases. Kaohsiung J Med Sci. 2003;19:105\u2013112.","DOI":"10.1016\/S1607-551X(09)70457-7"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Percy AK, Nobrega FT, Kurland LT. Optic neuritis and multiple sclerosis: an epidemiologic study. Arch Ophthalmol. 1972;87:135\u2013139.","DOI":"10.1001\/archopht.1972.01000020137004"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Rizzo JF, Lessell S. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Arch Ophthalmol. 1991;109:1668\u20131672.","DOI":"10.1001\/archopht.1991.01080120052024"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med. 1993;329:1764\u20131769.","DOI":"10.1056\/NEJM199312093292403"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2003;121:944\u2013949.","DOI":"10.1001\/archopht.121.7.944"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Keltner JL, Johnson CA, Spurr JO, et al; Optic Neuritis Study Group. Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1993;111:231\u2013234.","DOI":"10.1001\/archopht.1993.01090020085029"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Fang JP, Donahue SP, Lin RH. Global visual field involvement in acute unilateral optic neuritis. Am J Ophthalmol. 1999;128:554\u2013565.","DOI":"10.1016\/S0002-9394(99)00298-6"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Beck RW. The Optic Neuritis Treatment Trial: three-year follow-up results. Arch Ophthalmol. 1995;113:136\u2013137.","DOI":"10.1001\/archopht.1995.01100020014004"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol. 2004;137:77\u201383.","DOI":"10.1016\/S0002-9394(03)00862-6"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Kaufman DI, Trobe JD, Eggenberger ER, et al. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:2039\u20132044.","DOI":"10.1212\/WNL.54.11.2039"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581\u2013588.","DOI":"10.1056\/NEJM199202273260901"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Beck RW, Cleary PA; Optic Neuritis Study Group. Optic Neuritis Treatment Trial. One-year follow-up results. Arch Ophthalmol. 1993;111:773\u2013775.","DOI":"10.1001\/archopht.1993.01090060061023"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Biousse V, Calvetti O, Drews-Botsch CD, et al. Management of optic neuritis and impact of clinical trials: an international survey. J Neurol Sci. 2009;276:69\u201374.","DOI":"10.1016\/j.jns.2008.08.039"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Wakakura M, Mashimo K, Oono S, et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Jpn J Ophthalmol. 1999;43:133\u2013138.","DOI":"10.1016\/S0021-5155(98)00071-9"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Menon V, Mehrotra A, Saxena R, et al. Comparative evaluation of megadose methylprednisolone with dexamethasone for treatment of primary typical optic neuritis. Indian J Ophthalmol. 2007;55:355\u2013359.","DOI":"10.4103\/0301-4738.33821"},{"key":"ref=32","unstructured":"Chuenkongkaew W, Chirapapaisan N. Optic neuritis: characteristics and visual outcome. J Med Assoc Thai. 2003;86:238\u2013243."},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247:435\u2013442.","DOI":"10.1007\/s004150070172"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2015;8:CD001430.","DOI":"10.1002\/14651858.CD001430.pub4"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Kapoor R, Miller DH, Jones SJ, et al. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology. 1998;50:230\u2013237.","DOI":"10.1212\/WNL.50.1.230"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006;354:1273\u20131280.","DOI":"10.1056\/NEJMcp053247"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Sellebjerg F, Nielsen HS, Frederiksen JL, et al. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999;52:1479\u20131484.","DOI":"10.1212\/WNL.52.7.1479"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Morrow SA, Fraser JA, Day C, et al. Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol. March 5, 2018. [Epub ahead of print].","DOI":"10.1001\/jamaneurol.2018.0024"},{"key":"ref=39","unstructured":"Cleary PA, Beck RW, Bourque LB, et al. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J Neuroophthalmol. 1997;17:18\u201323."},{"key":"ref=40","unstructured":"Cole SR, Beck RW, Moke PS, et al. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial. Invest Ophthalmol Vis Sci. 2000;41:1017\u20131021."},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Mowry EM, Loguidice MJ, Daniels AB, et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry. 2009;80:767\u2013772.","DOI":"10.1136\/jnnp.2008.165449"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13:83\u201399.","DOI":"10.1016\/S1474-4422(13)70259-X"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Voss E, Raab P, Trebst C, et al. Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. Ther Adv Neurol Disord. 2011;4:123\u2013134.","DOI":"10.1177\/1756285611398702"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Malik A, Ahmed M, Golnik K. Treatment options for atypical optic neuritis. Indian J Ophthalmol. 2014;62:982\u2013984.","DOI":"10.4103\/0301-4738.145986"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84:1165\u20131173.","DOI":"10.1212\/WNL.0000000000001367"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Yamasaki R, Matsushita T, Fukazawa T, et al. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler J. 2016;22:1337\u20131348.","DOI":"10.1177\/1352458515617248"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Chrousos GA, Kattah JC, Beck RW, et al. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA. 1993;269:2110\u20132112.","DOI":"10.1001\/jama.1993.03500160080036"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Beck RW, Trobe JD. What we have learned from the Optic Neuritis Treatment Trial. Ophthalmology. 1995;102:1504\u20131508.","DOI":"10.1016\/S0161-6420(95)30839-1"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"Beck RW. The Optic Neuritis Treatment Trial. Implications for clinical practice. Optic Neuritis Study Group. Arch Ophthalmol. 1992;110:331\u2013332.","DOI":"10.1001\/archopht.1992.01080150029020"},{"key":"ref=50","unstructured":"Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol. 1994;14:38\u201344."},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Hattenhauer MG, Leavitt JA, Hodge DO, et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123;103\u2013107.","DOI":"10.1016\/S0002-9394(14)70999-7"},{"key":"ref=52","unstructured":"Boghen DR, Glaser JS. Ischemic optic neuropathy: the clinical profile and natural history. Brain. 1975;98:689\u2013708."},{"key":"ref=53","doi-asserted-by":"crossref","unstructured":"The Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA. 1995;273:625\u2013632.","DOI":"10.1001\/jama.273.8.625"},{"key":"ref=54","doi-asserted-by":"crossref","unstructured":"Preechawat P, Bruce BB, Newman NJ, et al. Anterior ischemic optic neuropathy in patients younger than 50 years. Am J Ophthalmol. 2007;144:953\u2013960.","DOI":"10.1016\/j.ajo.2007.07.031"},{"key":"ref=55","doi-asserted-by":"crossref","unstructured":"Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology. 2008;115:298\u2013305.","DOI":"10.1016\/j.ophtha.2007.05.027"},{"key":"ref=56","doi-asserted-by":"crossref","unstructured":"Hayreh SS. Anterior ischaemic optic neuropathy. Treatment, prophylaxis, and differential diagnosis. Br J Ophthalmol. 1974;58:981\u2013989.","DOI":"10.1136\/bjo.58.12.981"},{"key":"ref=57","doi-asserted-by":"crossref","unstructured":"Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2003;23:157\u2013163.","DOI":"10.1097\/00041327-200306000-00012"},{"key":"ref=58","doi-asserted-by":"crossref","unstructured":"Tesser RA, Niendorf ER, Levin LA. The morphology of an infarct in nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2003;110:2031\u20132035.","DOI":"10.1016\/S0161-6420(03)00804-2"},{"key":"ref=59","doi-asserted-by":"crossref","unstructured":"Hayreh SS, Zimmerman MB. Optic disc edema in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2007;245:1107\u20131121.","DOI":"10.1007\/s00417-006-0494-0"},{"key":"ref=60","doi-asserted-by":"crossref","unstructured":"Atkins EJ, Bruce BB, Newman NJ, et al. Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol. 2010;55:47\u201363.","DOI":"10.1016\/j.survophthal.2009.06.008"},{"key":"ref=61","doi-asserted-by":"crossref","unstructured":"Biousse V, Newman NH. Ischemic optic neuropathies. N Engl J Med. 2015;372:2428\u20132436.","DOI":"10.1056\/NEJMra1413352"},{"key":"ref=62","doi-asserted-by":"crossref","unstructured":"Prokosch V, Thanos S. Visual outcome of patients following NAION after treatment with adjunctive fluocortolone. Restor Neurol Neurosci. 2014;32:381\u2013389.","DOI":"10.3233\/RNN-120292"},{"key":"ref=63","doi-asserted-by":"crossref","unstructured":"Pakravan M, Sanjari N, Esfandiari H, et al. The effect of high-dose steroids, and normobaric oxygen therapy, on recent onset non-arteritic anterior ischemic optic neuropathy: a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2016;254:2043\u20132048.","DOI":"10.1007\/s00417-016-3451-6"},{"key":"ref=64","doi-asserted-by":"crossref","unstructured":"Luneau K, Newman NJ, Biousse V. Ischemic optic neuropathies. The Neurologist. 2008;14:341\u2013354.","DOI":"10.1097\/NRL.0b013e318177394b"},{"key":"ref=65","unstructured":"Quark Pharmaceuticals. Phase 2\/3, randomized, double-masked, sham-controlled trial of QPI-1007 in subjects with acute nonarteritic anterior ischemic optic neuropathy (NAION)."},{"key":"ref=66","doi-asserted-by":"crossref","unstructured":"Miller GR, Smith JL. Ischemic optic neuropathy. Am J Ophthalmol. 1966;62:103\u2013115.","DOI":"10.1016\/0002-9394(66)91685-0"},{"key":"ref=67","unstructured":"Foulds WS. Visual disturbances in systemic disorders. Optic neuropathy and systemic disease. Trans Ophthalmol Soc U K. 1970;89:125\u2013146."},{"key":"ref=68","doi-asserted-by":"crossref","unstructured":"Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol. 2008;246:1029\u20131046.","DOI":"10.1007\/s00417-008-0805-8"},{"key":"ref=69","doi-asserted-by":"crossref","unstructured":"Hayreh SS. Role of steroid therapy in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2010;30:386\u2013390.","DOI":"10.1097\/WNO.0b013e3181fab01b"},{"key":"ref=70","doi-asserted-by":"crossref","unstructured":"Rebolleda G, P\u00e9rez-L\u00f3pez M, Casas-LLera P, et al. Visual and anatomical outcomes of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids. Graefes Arch Clin Exp Ophthalmol. 2013;251:255\u2013260.","DOI":"10.1007\/s00417-012-1995-7"},{"key":"ref=71","doi-asserted-by":"crossref","unstructured":"Kinori M, Ben-Bassat I, Wasserzug Y, et al. Visual outcome of mega-dose intravenous corticosteroid treatment in non-arteritic anterior ischemic optic neuropathy \u2013 retrospective analysis. BMC Ophthalmol. 2014;14:62.","DOI":"10.1186\/1471-2415-14-62"},{"key":"ref=72","doi-asserted-by":"crossref","unstructured":"Alten F, Clemens CR, Heiduschka P, et al. Intravitreal dexamethasone implant [Ozurdex] for the treatment of nonarteritic anterior ischaemic optic neuropathy. Doc Ophthalmol. 2014;129:203\u2013207.","DOI":"10.1007\/s10633-014-9461-y"},{"key":"ref=73","doi-asserted-by":"crossref","unstructured":"Jonas JB, Spandau UH, Harder B, et al. Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2007;245:749\u2013750.","DOI":"10.1007\/s00417-006-0332-4"},{"key":"ref=74","doi-asserted-by":"crossref","unstructured":"Yaman A, Selver OB, Saatci AO, et al. Intravitreal triamcinolone acetonide injection for acute non-arteritic anterior ischaemic optic neuropathy. Clin Exp Optom. 2008;91:561\u2013564.","DOI":"10.1111\/j.1444-0938.2008.00287.x"},{"key":"ref=75","doi-asserted-by":"crossref","unstructured":"Kaderli B, Avci R, Yucel A, et al. Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2007;27:164\u2013168.","DOI":"10.1097\/WNO.0b013e31814a5a9a"},{"key":"ref=76","doi-asserted-by":"crossref","unstructured":"Radoi C, Garcia T, Brugniart C, et al. Intravitreal triamcinolone injections in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2014;252:339\u2013345.","DOI":"10.1007\/s00417-013-2499-9"},{"key":"ref=77","doi-asserted-by":"crossref","unstructured":"Lee V, Ford RL, Xing W, et al. Surveillance of traumatic optic neuropathy in the UK. Eye (Lond). 2010;24:240\u2013250.","DOI":"10.1038\/eye.2009.79"},{"key":"ref=78","doi-asserted-by":"crossref","unstructured":"Ford RL, Lee V, Xing W, et al. A 2-year prospective surveillance of pediatric traumatic optic neuropathy in the United Kingdom. J AAPOS. 2012;16:413\u2013417.","DOI":"10.1016\/j.jaapos.2012.04.009"},{"key":"ref=79","doi-asserted-by":"crossref","unstructured":"Kumaran AM, Sundar G, Lim TC. Traumatic optic neuropathy: a review. Craniomaxillofac Trauma Reconstr. 2015;8:31\u201341.","DOI":"10.1055\/s-0034-1393734"},{"key":"ref=80","doi-asserted-by":"crossref","unstructured":"McClenaghana FC, Ezra DG, Holmes SB. Mechanisms and management of vision loss following orbital and facial trauma. Curr Opin Ophthalmol. 2011;22:426\u2013431.","DOI":"10.1097\/ICU.0b013e3283499420"},{"key":"ref=81","doi-asserted-by":"crossref","unstructured":"Steinsapir KD, Goldberg RA. Traumatic optic neuropathy. Surv Ophthalmol. 1994;38:487\u2013518.","DOI":"10.1016\/0039-6257(94)90145-7"},{"key":"ref=82","doi-asserted-by":"crossref","unstructured":"Samardzic K, Samardzic J, Janjetovic Z, et al. Traumatic optic neuropathy-to treat or to observe? Acta Inform Med. 2012;20:131\u2013132.","DOI":"10.5455\/aim.2012.20.131-132"},{"key":"ref=83","doi-asserted-by":"crossref","unstructured":"Saxena R, Singh D, Menon V. Controversies in neuro-ophthalmology: steroid therapy for traumatic optic neuropathy. Indian J Ophthalmol. 2014;62:1028\u20131030.","DOI":"10.4103\/0301-4738.146021"},{"key":"ref=84","doi-asserted-by":"crossref","unstructured":"Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322:1405.","DOI":"10.1056\/NEJM199005173222001"},{"key":"ref=85","doi-asserted-by":"crossref","unstructured":"Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA. 1997;277:1597\u20131604.","DOI":"10.1001\/jama.1997.03540440031029"},{"key":"ref=86","doi-asserted-by":"crossref","unstructured":"Levin LA, Beck RW, Joseph MP, et al; International Optic Nerve Trauma Study Group. The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Ophthalmology. 1999;106:1268\u20131277.","DOI":"10.1016\/S0161-6420(99)00707-1"},{"key":"ref=87","doi-asserted-by":"crossref","unstructured":"Hsieh CH, Kuo YR, Hung HC, et al. Indirect traumatic optic neuropathy complicated with periorbital facial bone fracture. J Trauma. 2004;56:795\u2013801.","DOI":"10.1097\/01.TA.0000071298.97591.60"},{"key":"ref=88","doi-asserted-by":"crossref","unstructured":"Entezari M, Rajavi Z, Sedighi N, et al. High-dose intravenous methylprednisolone in recent traumatic optic neuropathy; a randomized double-masked placebo-controlled clinical trial. Graefes Arch Clin Exp Ophthalmol. 2007;245:1267\u20131271.","DOI":"10.1007\/s00417-006-0441-0"},{"key":"ref=89","doi-asserted-by":"crossref","unstructured":"Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet. 2005;365:1957\u20131959.","DOI":"10.1016\/S0140-6736(05)66552-X"},{"key":"ref=90","doi-asserted-by":"crossref","unstructured":"Sohn BJ, Chun BY, Kwon JY. The effect of an intravitreal triamcinolone acetonide injection for acute nonarteritic anterior ischemic optic neuropathy. Kor J Ophthalmol. 2009;23:59\u201361.","DOI":"10.3341\/kjo.2009.23.1.59"},{"key":"ref=91","unstructured":"Patel S, Lee Y. Non-arteritic ischemic optic neuropathy and intravitreal triamcinolone. Paper presented at: American Academy of Ophthalmology Annual Meeting. November 11\u201314, 2006; Las Vegas, NV."},{"key":"ref=92","unstructured":"Vidovi\u0107 T, Cerovski B, Peri\u0107 S, et al. Corticosteroid therapy in patients with non-arteritic anterior ischemic optic neuropathy. Coll Antropol. 2015;39:63\u201366."},{"key":"ref=93","doi-asserted-by":"crossref","unstructured":"Lai IL, Liao HT, Chen CT. Risk factors analysis for the outcome of indirect traumatic optic neuropathy with steroid pulse therapy. Ann Plast Surg. 2016;76:S60\u2013S67.","DOI":"10.1097\/SAP.0000000000000694"},{"key":"ref=94","doi-asserted-by":"crossref","unstructured":"Ropposch T, Steger B, Me\u00e7o C, et al. The effect of steroids in combination with optic nerve decompression surgery in traumatic optic neuropathy. Laryngoscope. 2013;123:1082\u20131086.","DOI":"10.1002\/lary.23845"},{"key":"ref=95","doi-asserted-by":"crossref","unstructured":"Miliaras G, Fotakopoulos G, Asproudis I, et al. Indirect traumatic optic neuropathy following head injury: report of five patients and review of the literature. J Neurol Surg A. 2013;74:168\u2013174.","DOI":"10.1055\/s-0032-1330115"},{"key":"ref=96","doi-asserted-by":"crossref","unstructured":"Soldevilaa L, Cano-Parrab J, Ruizc A, et al. Traumatic optic neuropathy: to treat or not to treat? Report of two cases. Arch Soc Esp Oftalmol. 2013;88:116\u2013119.","DOI":"10.1016\/j.oftale.2011.10.006"},{"key":"ref=97","doi-asserted-by":"crossref","unstructured":"Tandon A, Dorrepaal SJ. Traumatic optic neuropathy\u2014to treat or not to treat? Can J Ophthalmol. 2009;44:e53\u2013e54.","DOI":"10.3129\/i09-133"},{"key":"ref=98","doi-asserted-by":"crossref","unstructured":"Dojcinovic I, Richter M. Mucormycoses: serious complication of high-dose corticosteroid therapy for traumatic optic neuropathy. Int J Oral Maxillofac Surg. 2008;37:391\u2013394.","DOI":"10.1016\/j.ijom.2007.09.177"},{"key":"ref=99","unstructured":"Das H, Badhu BP, Gautam MA. Indirect traumatic optic neuropathy\u2014retrospective interventional case series from tertiary care center in Eastern Nepal. J Nepal Med Assoc. 2007;46:57\u201361."},{"key":"ref=100","doi-asserted-by":"crossref","unstructured":"Acat\u00fcrk S, Sek\u00fc\u00e7o\u011flu T, Kesikt\u00e4s E. Mega dose corticosteroid treatment for traumatic superior orbital fissure and orbital apex syndromes. Ann Plast Surg. 2004;53:60\u201364.","DOI":"10.1097\/01.sap.0000106424.54415.dc"},{"key":"ref=101","doi-asserted-by":"crossref","unstructured":"Rajiniganth MG, Gupta AK, Gupta A, et al. Traumatic optic neuropathy: visual outcome following combined therapy protocol. Arch Otolaryngol Head Neck Surg. 2003;129:1203\u20131206.","DOI":"10.1001\/archotol.129.11.1203"},{"key":"ref=102","doi-asserted-by":"crossref","unstructured":"Mahapatraa AK, Tandonb DA. Traumatic optic neuropathy in children: a prospective study. Pediatr Neurosurg. 1993;19:34\u201339.","DOI":"10.1159\/000120698"},{"key":"ref=103","doi-asserted-by":"crossref","unstructured":"Joseph MP, Lessell S, Rizzo J, et al. Extracranial optic nerve decompression for traumatic optic neuropathy. Arch Ophthalmol. 1990;108:1091\u20131093.","DOI":"10.1001\/archopht.1990.01070100047032"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T17:03:33Z","timestamp":1604509413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/apjoo\/Fulltext\/2018\/07000\/Steroid_Treatment_of_Optic_Neuropathies.2.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":103,"URL":"https:\/\/doi.org\/10.22608\/apo.2018127","relation":{},"ISSN":["2162-0989","2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"},{"value":"2162-0989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}